Wasatch Advisors LP lessened its stake in Cerus Corporation (NASDAQ:CERS – Free Report) by 35.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,383,899 shares of the biotechnology company’s stock after selling 1,897,237 shares during the quarter. Wasatch Advisors LP owned about 1.69% of Cerus worth $9,881,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Cubist Systematic Strategies LLC grew its stake in Cerus by 152.4% during the first quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock worth $145,000 after buying an additional 62,854 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Cerus by 291.6% during the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after acquiring an additional 1,064,133 shares during the period. Millennium Management LLC lifted its holdings in shares of Cerus by 12.0% during the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock worth $4,479,000 after acquiring an additional 344,395 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cerus during the 1st quarter worth approximately $32,000. Finally, Rhumbline Advisers boosted its position in shares of Cerus by 6.8% during the 2nd quarter. Rhumbline Advisers now owns 268,946 shares of the biotechnology company’s stock worth $379,000 after acquiring an additional 17,039 shares in the last quarter. Institutional investors own 78.37% of the company’s stock.
Cerus Price Performance
Shares of NASDAQ:CERS opened at $2.71 on Thursday. The company has a market cap of $546.12 million, a price-to-earnings ratio of -90.33 and a beta of 1.81. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.83 and a quick ratio of 1.07. The firm has a 50 day simple moving average of $2.80 and a 200 day simple moving average of $2.42. Cerus Corporation has a one year low of $1.15 and a one year high of $3.47.
Insider Activity at Cerus
In other Cerus news, CFO Kevin Dennis Green sold 33,676 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total value of $99,007.44. Following the completion of the transaction, the chief financial officer directly owned 1,062,188 shares in the company, valued at approximately $3,122,832.72. This trade represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Chrystal Jensen sold 24,329 shares of Cerus stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $2.94, for a total value of $71,527.26. Following the sale, the insider directly owned 966,657 shares in the company, valued at $2,841,971.58. The trade was a 2.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 239,404 shares of company stock worth $697,893 over the last 90 days. 5.30% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Several research analysts have commented on CERS shares. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Zacks Research raised Cerus from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Finally, BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a report on Friday, May 1st. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.00.
Check Out Our Latest Report on Cerus
About Cerus
Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.
The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.
Featured Stories
- Five stocks we like better than Cerus
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.
